Tesamorelin

What it is

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH) that stimulates the synthesis and release of endogenous growth hormone (GH) from the pituitary gland in an episodic, pulsatile manner. By augmenting pulsatile GH secretion, tesamorelin subsequently increases insulin-like growth factor-1 (IGF-1) levels. This GH/IGF-1 axis augmentation selectively reduces visceral adipose tissue (VAT) without significantly affecting subcutaneous adipose tissue. Unlike exogenous GH administration, tesamorelin acts physiologically through the pituitary gland, restoring a more normal GH secretion profile. It also modulates hepatic gene pathways involved in inflammation, tissue repair, and cell division, and upregulates hepatic oxidative phosphorylation gene sets. Additionally, tesamorelin has been shown to reduce circulating markers of immune activation and modulate IGF-binding proteins.

Class: Growth hormone-releasing hormone (GHRH) analogue / synthetic growth hormone secretagogue

What it's studied for

• HIV-associated lipodystrophy / excess visceral abdominal fat in people with HIV Human RCT
  • Tesamorelin 2 mg SC daily for 6 months significantly reduced visceral adipose tissue (mean change -34 cm² vs +8 cm² placebo; treatment effect -42 cm²; P=0.005) and liver fat (net treatment effect -2.9% lipid-to-water percentage; P=0.003) in 50 HIV-infected patients with abdominal fat accumulation. PMID 25038357 Stanley TL et al. JAMA 2014
  • Systematic review of two 26-week Phase 3 RCTs: tesamorelin SC significantly reduced VAT and waist circumference in HIV-associated lipodystrophy; VAT reduction maintained at 52 weeks with continued therapy; discontinuation led to VAT reaccumulation. Serious adverse events occurred in <4% of patients. PMID 21668043 Dhillon S. Drugs 2011
  • Systematic review and meta-analysis of 4 RCTs (909 patients): tesamorelin 2 mg significantly reduced VAT (MD -21.47 cm²; P=0.002), waist circumference (MD -1.61 cm; P<0.00001), trunk fat (MD -1.20 kg; P<0.00001), and increased lean body mass (MD 1.42 kg; P<0.00001). Growth hormone-related adverse effects observed. PMID 42538058 Mohammed Ditta A et al. J Int Assoc Provid AIDS Care 2026
  • Meta-analysis of 5 RCTs: tesamorelin significantly reduced VAT (MD -27.71 cm²), trunk fat, limb fat, hepatic fat percentage (MD -4.28%), and waist circumference; increased lean body mass (MD 1.42 kg). No significant change in subcutaneous fat, BMI, or CD4+ T-cell counts. Adverse events included arthralgia, myalgia, par PMID 41545261 Badran AS et al. Obes Res Clin Pract 2026
  • In 38 PWH on integrase inhibitor (INSTI)-based regimens, tesamorelin 2 mg once daily vs placebo for 12 months led to significant reductions in visceral fat (median -25 vs +14 cm²; P=0.001), hepatic fat (-4.2% vs -0.5%; P=0.01), and trunk-to-appendicular fat ratio (P=0.03), with no exacerbation of glycemic control. PMID 38905488 Russo SC et al. AIDS 2024
  • Randomized double-blind multicentre trial of 61 HIV-infected patients with NAFLD: tesamorelin 2 mg daily vs placebo for 12 months reduced hepatic fat fraction (absolute effect -4.1%, 95% CI -7.6 to -0.7; P=0.018); 35% of tesamorelin vs 4% of placebo group achieved HFF <5% (P=0.0069). Fasting glucose and HbA1c not signi PMID 31611038 Stanley TL et al. Lancet HIV 2019
  • Post-hoc analysis of two Phase 3 trials (tesamorelin 2 mg n=543, placebo n=263): metabolic syndrome (NCEP criteria), triglycerides >1.7 mmol/L, and white race predicted greater VAT reduction at 6 months. Odds of VAT reduction to <140 cm² were 3.9× greater for tesamorelin vs placebo. PMID 26457580 Mangili A et al. PLoS One 2015
• HIV-associated non-alcoholic fatty liver disease (NAFLD) / metabolic dysfunction-associated steatotic liver disease (MASLD) Human RCT
  • Tesamorelin 2 mg daily for 12 months significantly reduced hepatic fat fraction and prevented fibrosis progression in HIV-associated NAFLD compared to placebo. PMID 31611038 Stanley TL et al. Lancet HIV 2019
  • Hepatic transcriptomic analysis from paired biopsies in a RCT: tesamorelin increased oxidative phosphorylation gene sets and decreased inflammation/tissue repair/cell division gene sets; correlated with improved fibrosis-related gene score. PMID 32701508 Fourman LT et al. JCI Insight 2020
  • Tesamorelin led to significant reductions in plasma VEGFA, TGFB1, and CSF1 vs placebo; reductions in VEGFA and CSF1 correlated with decline in NAFLD activity score; decreases in TGFB1 and CSF1 associated with reduced fibrosis gene score. PMID 34006921 Fourman LT et al. Sci Rep 2021
  • In HIV-associated NAFLD, visceral fat was positively associated with ALT (P=0.01); tesamorelin VAT responders experienced greater reductions in ALT (-8.9 vs +1.4 U/L; P=0.004) and AST (-3.8 vs +0.4 U/L; P=0.04) vs non-responders over 26 weeks. PMID 28832410 Fourman LT et al. Clin Infect Dis 2021
• Body composition improvement (visceral fat, lean mass, muscle quality) in people with HIV Human RCT
  • Secondary analysis of two RCTs: tesamorelin responders (VAT decrease ≥8%) showed significantly greater increases in trunk muscle density (coefficient 1.56–4.86 HU; all P<0.005) and lean muscle area of all four truncal groups compared to placebo over 26 weeks. PMID 31237318 Adrian S et al. J Frailty Aging 2019
  • Tesamorelin increased VAT and SAT density (fat quality) independent of fat quantity changes over 26 weeks in PWH (VAT +6.2 vs +0.3 HU placebo; P<0.0001; SAT +4.0 vs +0.3 HU; P<0.0001). PMID 33756511 Lake JE et al. AIDS 2021
• Metabolic effects: triglycerides, inflammatory markers, cardiovascular risk markers Human RCT
  • Phase 3 RCT of 410 HIV-infected patients: tesamorelin significantly decreased tPA antigen (P<0.05) and changes in inflammatory markers were associated with VAT change; modest beneficial effects on adiponectin and fibrinolytic markers observed. PMID 21516030 Stanley TL et al. AIDS 2011
  • In 60 obese subjects with reduced GH, tesamorelin 2 mg daily for 12 months significantly reduced VAT (-35 cm² treatment effect; P=0.003), carotid IMT (-0.04 mm; P=0.02), log CRP (-0.15 mg/L; P=0.04), and triglycerides (-37 mg/dL; P=0.02) vs placebo. No significant effects on fasting or 2-hr glucose or HbA1c. PMID 23015655 Makimura H et al. J Clin Endocrinol Metab 2012
  • Phase 3 RCT: tesamorelin responders (≥8% VAT reduction) had greater triglyceride reductions at 26 and 52 weeks and attenuated changes in fasting glucose and HbA1c vs non-responders. PMID 22495074 Stanley TL et al. Clin Infect Dis 2012
• Glycemic safety in type 2 diabetes Human RCT
  • 12-week RCT of 53 patients with type 2 diabetes: no significant differences between placebo, 1 mg, and 2 mg tesamorelin groups in relative insulin response, fasting glucose, HbA1c, or diabetes control. Total cholesterol and non-HDL cholesterol significantly decreased from baseline in the 2 mg group (P<0.05 vs placebo). PMID 28617838 Clemmons DR et al. PLoS One 2017
• Neurocognitive function in HIV with abdominal obesity Human RCT
  • Phase 2 RCT (n=73): tesamorelin 2 mg SC daily vs standard of care for 6 months showed trend toward improved neurocognitive performance (P=0.060) but between-group difference was not significant (P=0.673). Tesamorelin group had greater reduction in waist circumference (median difference -2.7 cm; P=0.015). Study was unde PMID 39813152 Ellis RJ et al. J Infect Dis 2025
• Mitochondrial function (phosphocreatine recovery) in obese adults with reduced GH Human RCT
  • 12-month RCT of 39 obese adults with reduced GH: significant positive relationship between increases in IGF-1 and improvements in PCr recovery (R=0.56; P=0.01), with stronger association among tesamorelin-treated subjects only (R=0.71; P=0.03), suggestive of improvements in mitochondrial function. PMID 24178787 Makimura H et al. J Clin Endocrinol Metab 2014
• Physical function in older adults with HIV (ongoing trial) Human RCT
  • TRIUMPH trial protocol: two-site, double-blind RCT of 100 sedentary older adults (aged 50-80) with HIV who are frail or at risk for frailty and have excess abdominal adiposity. Participants randomized to tesamorelin or placebo as adjunct to home-based exercise for 24 weeks. Endpoints include physical function, muscle c PMID 42419889 Erlandson KM et al. BMJ Open 2026 (TRIUMPH protocol)
• Orthopaedic / sports medicine / musculoskeletal injury Animal studies only
  • Narrative review: tesamorelin, approved for HIV-associated lipodystrophy, has no supporting orthopaedic evidence. Remains investigational for musculoskeletal indications. PMID 41476424 Mayfield CK et al. Am J Sports Med 2026
  • Structured narrative review: growth hormone axis secretagogues including tesamorelin remain investigational for sports medicine, with uncertain safety profiles and product quality concerns. PMID 42160466 Villegas Meza AD et al. JBJS Rev 2026

Community-reported dosing

Tier key: Research = PMID-cited study · [C] = scraped community source · [S] = model-synthesized from aggregate community reports (softer evidence). How we source.

Safety signals

• Injection-site reactions (erythema, localised complaints): more frequent in tesamorelin than placebo groups in clinical trials, though none judged serious in the NAFLD RCT. PMID 31611038
• Injection-site reactions including erythema reported in meta-analysis of RCTs. PMID 41545261
• Arthralgia reported as an adverse event in RCTs (a known GH-related effect). PMID 41545261
• Myalgia reported as an adverse event in RCTs. PMID 41545261
• Paresthesia reported as an adverse event in RCTs. PMID 41545261
• Headache reported as a treatment-emergent adverse event associated with GH therapy. PMID 21668043
• Peripheral oedema reported as a treatment-emergent adverse event associated with GH therapy. PMID 21668043
• Transient early increase in fasting glucose at 2 weeks (mean +9 mg/dL vs +2 mg/dL placebo; P=0.03), not sustained at 6 months. PMID 25038357
• Higher discontinuation rates with tesamorelin vs placebo in meta-analysis (RR 2.25; 95% CI 0.98–5.17; P=0.06), though not statistically significant. PMID 42538058
• Treatment-emergent serious adverse events in <4% of patients during 26 weeks of therapy in Phase 3 trials, most being injection-site reactions or GH-related effects. PMID 21668043
• Visceral adipose tissue reaccumulates promptly upon discontinuation of tesamorelin. PMID 21668043
• Reported adverse effects across GHRH analogue class in self-administration context include endocrine/metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention, musculoskeletal symptoms, and injection-site reactions. PMID 42395176

Contraindications

• Active malignancy: participants with malignancy were excluded from the neurocognitive Phase 2 RCT of tesamorelin, reflecting standard GH-axis safety concerns. PMID 39813152
• Conditions other than HIV causing neurocognitive impairment were an exclusion criterion, indicating that tesamorelin has not been studied in this context. PMID 39813152
• Active substance use disorder was an exclusion criterion in the neurocognitive RCT. PMID 39813152